Last updated: 2026-09-16 09:45:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
CareDx, Inc. (CDNA) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $52.96, with a market capitalisation of $2.71B and a P/E ratio of 24.53. Over the past 52 weeks, its price has ranged from $13.72 to $53.74. This page covers its latest market performance, valuation, price trends and company information.
$2.71B | |
$52.55 | |
$99.83 | |
$0.76 | |
$52.64 | |
225.00 | |
1.15M | |
24.53 | |
$53.74 | |
$13.72 | |
-- | |
-- |
CareDx, Inc. (CDNA) is trading at $52.96 in pre-market trading as of 2026-09-16 09:21:00, up 0.61% ($0.32) from the previous close of $52.64
Pre-market trading shows how investors are pricing CDNA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, CareDx, Inc. (CDNA) moved from $50.88 to $52.96, representing a gain of 4.09% ($2.08).
The stock traded between $48.64 and $53.74 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.07 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 98.1%
CDNA is currently trading at $52.96, placing it 98.1% of the way from its 52-week low of $13.72 to its 52-week high of $53.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 765 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CareDx, Inc. (CDNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.